Holen Sie sich die Stockscreener-App
2.61
2.61%
-0.07
Vorhandelsmarkt:
2.61
Schlusskurs vom Vortag:
$2.68
Offen:
$2.74
24-Stunden-Volumen:
510.58K
Relative Volume:
0.37
Marktkapitalisierung:
$23.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.16M
KGV:
-7.6765
EPS:
-0.34
Netto-Cashflow:
$-39.49M
1W Leistung:
-8.10%
1M Leistung:
-7.45%
6M Leistung:
-20.43%
1J Leistung:
-29.27%
1-Tages-Spanne:
$2.54
$2.7499
1-Wochen-Bereich:
$2.44
$2.84
52-Wochen-Spanne:
$2.11
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Firmenname
Dare Bioscience Inc
Sektor
Branche
Telefon
858-926-7655
Adresse
3655 NOBEL DRIVE, SAN DIEGO, CA
Vergleichen Sie DARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.61 | 25.14M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten
UPDATEDaré Bioscience to Host August 6 Webinar: The DARE - GlobeNewswire
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ DifferenceThe Sildenafil Cream That Raises the Bar - GlobeNewswire
Daré Bioscience Reports Positive Contraception Trial Results as Smart Drug Delivery Platform Shows Broader Potential - Femtech Insider
Dare Bioscience stock holds Buy rating at H.C. Wainwright on positive trial data - Investing.com Canada
3 Penny Stocks to Watch Now, 7/15/25 - TipRanks
Daré Bioscience reports positive interim results for hormone-free contraceptive - Investing.com Australia
Small Healthcare Stocks Enjoy Big Wins On Deal News - Finimize
Dare Bioscience Surges to 200th in Market Rankings with $47.4 Million Turnover - AInvest
Douglas Tsao Recommends ‘Buy’ for Daré Bioscience: Ovaprene’s Promising Potential and Financial Prospects - TipRanks
Crude Oil Moves Lower; Daré Bioscience Shares Jump - inkl
Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene - TipRanks
Daré Bioscience stock soars after positive interim Phase 3 contraceptive results - Investing.com India
Daré Bioscience Soars 250% on Positive Ovaprene Trial Data - Wall Street Pit
Dare Bioscience’s Unforeseen Stock Skyward Leap - StocksToTrade
US Stocks Edge Lower; Fastenal Posts Upbeat Earnings - Benzinga
Dare Bioscience Reflects on Grant Milestone - timothysykes.com
Daré Bioscience reports positive interim results for hormone-free contraceptive By Investing.com - Investing.com South Africa
Why Is Daré Bioscience Stock (DARE) Up 240% Today? - TipRanks
Dare Bioscience Announces Positive Results From Hormone-Free Contraceptive Trial; Shares Surge - MarketScreener
Daré Bioscience Announces Positive Phase 3 Trial Results - TipRanks
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - The Manila Times
Daré Bioscience Announces Positive Interim Results from Phase 3 Trial of Hormone-Free Contraceptive Ovaprene® - Quiver Quantitative
Dare Bioscience Plunges 11.33% Amid Market Shifts - AInvest
Daré Bioscience receives $6 million installment for contraceptive device - Investing.com Australia
Daré Bioscience Receives $6 Million Non-Dilutive Grant - GlobeNewswire
Dare Bioscience Sees Stock Surge Amid Strategic Collaborations - StocksToTrade
Daré Bioscience receives $6 million installment for contraceptive device By Investing.com - Investing.com South Africa
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders - GlobeNewswire
Daré's Smart Drug Delivery Platform Secures $6M Grant, Eyes Expansion into $B Obesity Market - Stock Titan
Dare Bioscience shareholders approve board nominees and stock plan amendment - Investing.com
Daré Bioscience Stockholder Meeting Approves Key Proposals - TipRanks
Daré Bioscience Gains Nasdaq Compliance Extension Approval - TipRanks
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders | DARE Stock News - GuruFocus
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders - GlobeNewswire
Daré Bioscience Stockholders Must Vote by July 8 for Crucial Annual Meeting - Stock Titan
Daré Bioscience Announces Corporate Presentation for Investors - TipRanks
Brokers Offer Predictions for Daré Bioscience Q1 Earnings - Defense World
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
H.C. Wainwright maintains Buy rating on Dare Bioscience stock By Investing.com - Investing.com Canada
Daré Bioscience partners with Rosy Wellness for new women’s health cream By Investing.com - Investing.com South Africa
Daré Bioscience and Rosy Wellness Announce Strategic - GlobeNewswire
Daré Bioscience partners with Rosy Wellness for new women’s health cream - Investing.com
Dare Bioscience (DARE) Joins Forces with Rosy Wellness for Product Campaign | DARE Stock News - GuruFocus
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream - Yahoo Finance
Daré Bioscience, Rosy Wellness to Collaborate on DARE to PLAY Sildenafil Cream Marketing - AInvest
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Q2 EPS Estimate for Daré Bioscience Increased by Analyst - Defense World
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Daré Bioscience’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2025 Earnings Call Transcript - Insider Monkey
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates - MSN
Finanzdaten der Dare Bioscience Inc-Aktie (DARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):